October's Wild Stock Picks: Bears Beware!

Wall Street's Fresh Holy Trinity of "WTF Is This Stock Smoking?" – October 3, 2026 Edition[1]

Back at it, you beautiful degenerates. Markets are still a glorious shitshow—AI hype juicing the Nasdaq while the Dow sits there like a bored hooker and crude oil bounces around like a meth-fueled pinball. I scoured the latest short-interest data (Sep 25 settlement vibes dominating) for three brand-new names where the bears are piled on like it's a clearance sale on doom, and the bulls are yelling "squeeze this, motherfucker." No repeats of the usual suspects like HTZ/PLCE/QUBT/GRPN/SOUN/SERV/LCID/METC/RH/etc.—just fresh chaos with shorts north of 35% screaming "prove me wrong, bitch." Here's the latest holy trinity of pure, unfiltered "who the fuck knows?"

1. RXRX (Recursion Pharmaceuticals): The AI Drug-Hunting Lab Rat

The Bull Case (We're Cracking the Code of Life—AI-Powered Pipeline to the Moon):
Bulls are creaming over Recursion's AI/ML platform that turns biology into a video game of molecule prediction, massive datasets, and a pipeline targeting everything from rare diseases to oncology. Shorts are stacked heavy (~35% of float), but any positive clinical readouts, partnership deals, or "AI finally cures shit" narrative could trigger a violent short squeeze. "We've got the tech edge and the data moat—watch the platform monetize and shorts get algorithmically owned" is the cope. Revenue ramp? Pipeline catalysts? Shorts left in the dust.[1]

The Bear Case (All Hype, No Approved Drugs—Classic Biotech Cash Incinerator):
Reality check: Pre-revenue (or damn close), insane cash burn, insanely long timelines to actual approvals/sales, brutal competition from bigger pharma and other AI-biotech plays, and a valuation that assumes the AI magic translates to real, approvable drugs. High shorts reflect the market's "yeah, right" on execution and dilution risk. One failed trial, regulatory smackdown, or funding crunch and it's back to square one or worse. Recursion? More like recursion into shareholder value destruction.[2]

My First-Principles Breakdown:
Strip it down: Drug discovery wins on probability of success, capital efficiency, and differentiation—not just flashy AI demos. RXRX has a differentiated platform and early data, but "platform scaling" assumes the tech edge survives real-world validation, regulatory hurdles, and deeper-pocketed rivals. Shorts correctly price in the binary technical/financial risks in a capital-intensive game; bulls correctly price in the asymmetric upside if AI meaningfully bends the discovery curve. High-vol biotech lottery ticket—entertaining as hell, size accordingly or cry later.

2. NEGG (Newegg Commerce): The Tech Retail Underdog Fighting the Amazon Beast

The Bull Case (We're the Niche King of PC Parts and Geek Gear—E-commerce Revival Incoming):
Bulls hype the brand's heritage in specialty tech retail, potential for marketplace growth, international expansion, and "back-to-gaming/PC building" tailwinds. Shorts are piled on (~35% of float), but any sales beat, inventory optimization, or consumer spending resilience could spark a squeeze. "We've got the loyal nerd base and we're adapting to the digital age better than the big boys" is the mantra—slim the ops, fatten the margins, and watch shorts eat their RGB keyboards.[1]

The Bear Case (Dying Niche Player in a Fast-Fashion/Amazon Apocalypse):
Reality bites: Brutal competition from Amazon, Best Buy, and direct manufacturers; margin pressure; inventory risks in a cyclical tech space; and a retail model that screams "market share erosion ahead." High shorts aren't random—they're the market saying "this growth story is hardware-dependent and threadbare." One bad quarter, macro dip, or execution miss and it's more discounting or worse. Newegg? More like "new egg on your face."[1]

My First-Principles Breakdown:
Fundamentally, specialty e-commerce lives or dies on brand loyalty, supply chain efficiency, and discretionary/tech spending. NEGG has a recognizable niche and potential for leaner operations/marketplace leverage, but "revival" requires consistent growth in a hyper-competitive space dominated by giants. Shorts flag structural headwinds; bulls flag optionality if enthusiasts keep clicking. High-risk retail bet with squeeze lottery potential—trade the narrative, not your retirement.

3. CLSK (CleanSpark): The Bitcoin Miner with Energy (and AI?) Dreams

The Bull Case (We're the Efficient Crypto Infrastructure Play—Bitcoin Boom + Energy Pivot = Glory):
Bulls see a lean Bitcoin miner scaling hash rate with renewable-ish energy plays, potential AI/data center synergies, and "digital gold + energy transition" tailwinds. Shorts are aggressive (~40%+ in recent scans), setting up a moonshot on any BTC rally, operational beats, or expansion news. "We're not just another miner; we're positioned for the next wave" is the rally cry—hash harder and shorts get left in the blockchain dust.[3]

The Bear Case (Volatile Crypto Spec with Dilution and Execution Headaches):
Reality: Bitcoin price swings destroy margins, massive capex needs, competition from bigger miners, energy cost volatility, and a valuation that prices in perfection. Shorts see through the "pivot" hype—most of this is still speculative bets on crypto staying hot while burning cash on growth. One BTC dip, missed target, or dilution wave and the miner dream evaporates. CleanSpark? More like "clean up this mess."[4]

My First-Principles Breakdown:
At core, crypto mining is a probability game of energy costs, hash rate efficiency, and capital allocation—BTC price and halving cycles matter more than marketing. CLSK has operational discipline and an energy angle, but "AI pivot" assumes the tech edge survives real-world economics and brutal competition. Shorts correctly flag the cyclical/funding risks; bulls correctly flag the asymmetric upside if crypto or energy demand clicks. High-volatility speculation—lottery ticket with real infrastructure intrigue.

Bottom Line (No Crystal Ball, Just Brutal Logic):
These three capture the current divided vibe: AI-biotech moonshot, niche tech retail adaptation bet, and crypto/energy infrastructure gamble. The common thread? Sky-high skepticism via shorts, but real catalysts that could flip the script. Markets adore punishing uncertainty—and these names are marinated in it. Laugh at the chaos, size positions like your rent depends on it (or don't), and remember: this is entertainment with numbers. Your move, degenerates.

Sources for the terminally curious (verify this shit yourself): Recent short-interest trackers and screens (e.g., FindMyMoat, Benzinga, Tapeboard, ChartMill, TipRanks) highlighting elevated levels in RXRX, NEGG, and CLSK; market commentary on the underlying sector debates. Always do your own digging—these are snapshots of a deranged market. Trade responsibly, or at least don't cry when it goes tits up.